New reimbursement act – a survey of pharmaceutical companies
From the very start the act on the reimbursement of drugs, food for special dietary use and medical devices had been controversial for producers and pharmaceutical wholesalers, as well as the staff of hospitals and pharmacies, doctors and patients. Most changes and doubts related to the issues of reimbursed medicines. The aim of our client – an international auditing and consulting company – was to learn about the opinion of pharmaceutical companies on the new regulations.
The project comprised conducting over 80 quantitative interviews with the executive staff of pharmaceutical companies – medicine manufacturers, distributors, and independent wholesalers. The CATI survey involved only companies that offer reimbursed medicines. The questionnaire covered a number of questions on the process of introducing the act and its current shape (reservations, ambiguity, positive aspects), the impact on the current activity of the individual participants of the pharmaceutical market, and the desired directions of change on the market.
Value for the client
The client received a report containing the summary of the findings and an insightful analysis of the new reimbursement act. It presented the opinions collected from pharmaceutical of three activity profiles. It allowed considering different points of view on the question of reimbursement of medicines, the ban on incentives (e.g. discounts), or the introduction of new limit groups.
- Hepatitis C treatment in Poland – new drug concept test
- Healthcare service offer survey
- A study of the dermocosmetics market in Poland
- OTC market in Poland
- Biological and biosimilars drug market in Poland
- Private healthcare market in Central Europe